A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy.
Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , , |
---|---|
Μορφή: | Journal article |
Έκδοση: |
1999
|